Masimo has announced that Cambridge University Hospitals NHS Foundation Trust, United Kingdom (UK) is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicine programs. Masimo W1, which offers accurate, continuous measurements of key physiological parameters, is available in the UK as a medical device that integrates with the Masimo SafetyNet® remote patient management platform.
What does the partnership mean for Cambridge?
Cambridge launched its virtual ward program in 2022, as part of a National Health Service England telehealth initiative designed to promote earlier patient discharge to the home.
More than 20 specialities across the hospital now participate in Cambridge’s virtual program, which sends patients home with a variety of Masimo products – such as MightySat® and wearable medical devices like Radius PPG®, Radius Tº®, and now Masimo W1 – that allow monitoring and vitals signs data to be relayed to clinicians back at the hospital.
Via the Masimo SafetyNet clinician dashboard, clinicians can monitor patients’ physiological status from afar, allowing patients to stay monitored in the comfort of their own homes.
Commenting on the device, Dr. Iain Goodhart, Clinical Director of the Virtual Hospital Program at Cambridge University Hospitals NHS Foundation Trust, said, “Masimo W1 will help us expand our Virtual Hospital program by offering continuous monitoring of oxygen saturation and pulse rate, as well as ECG spot-checking, in a comfortable, easy to use watch.”
“We hope that, integrated with Masimo SafetyNet, the telehealth platform we already use, Masimo W1 can help support more confident patient discharge and management for patients who, before our Virtual Hospital program, might have needed to stay longer in the hospital. We’re excited to incorporate Masimo W1 into our telehealth practices,” Dr. Iain added.
What does the partnership mean for Masimo?
Joe Kiani, Founder and CEO of Masimo, commented, “Masimo W1 represents not only the future of personal health but is playing a vital role in the expansion of remote healthcare.”
“Built on our decades of expertise developing breakthrough noninvasive medical monitoring tech, Masimo W1 is designed to aid valued hospital partners like Cambridge in accelerating their virtual hospital and telehealth programs – helping to improve patient outcomes while reducing the cost of care. We are excited for Cambridge clinicians and patients,” Kiani said.
Masimo W1 for use in medical applications is pending FDA clearance in the U.S.